Saturday 17 October 2026
Export VRPX’s income statement to Excel — free account
Virpax Pharmaceuticals, Inc.
VRPX Healthcare Biotechnology
In the quarter to December 2024, EPS grew 153.6% and free cash flow grew 4.68%, each against the same quarter a year earlier.
0.00
0.00
NaN
Follow VRPX
| Older periods | Mar '24 | Jun '24 | Sep '24 | Dec '24 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(241.52%) | (362.29%) | (594.46%) | (2,364.98%) | |
| (156.21%) | (185.81%) | (198.45%) | (215.80%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
1,391.91% | 616.46% | 645.30% | 1,320.56% | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(332.79) | (190.08) | (90.47) | (98.20) | |
Free Cash Flow |
(15.57) | (15.04) | (16.85) | (16.71) | |
| Other line items | |||||
Cash ROIC |
(2,386.20%) | 1,627.56% | 828.44% | (2,788.74%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
— | (240.22) | (101.44) | (117.40) | |
Operating CF/Net income |
0.92 | 0.87 | 1.27 | 1.39 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(332.79) | (190.08) | (90.47) | (98.20) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates